Study of factors linked to weight loss in amyotrophic lateral sclerosis
Collects blood samples and questionnaires from adults with amyotrophic lateral sclerosis to study weight loss.
Key facts
- Who runs it
- University Hospital, Limoges
- Where
- Lille, Limoges, Marseille, Montpellier, Nice, Paris, and Tours, FranceSee the 7 sitesAlso in 1 other country, 2 sites
- Trial code
- Registry title
- French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 17 Sept 2024
- Expected to end
- 30 Sept 2029
- Type of study
- Interventional
- Treatments tested
- Blood sample
- Record updated
- 6 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults newly diagnosed with amyotrophic lateral sclerosis (ALS) at one of the nine referral centres in France and Germany. It studies what is linked to weight loss in ALS.
- Age
- Adults over 18 years old.
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed ALS: definite, probable, probable laboratory-supported, or possible ALS, by El Escorial revised criteria and Gold Coast criteria.
Main reasons for not taking part
- Cannot understand the requirements of the protocol
- Cannot understand and sign the informed consent form because of cognitive problems
- Will not accept Riluzole therapy during follow-up
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Incident cases included at the time of diagnosis with a definite, probable, probable laboratory-supported, or possible ALS according to El Escorial revised criteria and Gold Coast criteria for early diagnosis
- Incident ALS cases identified and followed-up in the participant ALS \& Other Motor Neuron Diseases Referral Centres: seven in France and two in Germany
- Patients who signed the informed consent form
- Adults aged >18 years old
Who cannot take part
- Patients who will not accept Riluzole therapy during their follow-up
- Inability to understand the requirements of the protocol
- Cognitive inability to sign and comprehend the informed consent form
Where in France
Also in 1 other country, 2 sites
- CHU de LilleLille, FranceContact: Veronique DANEL-BRUNAUD, Medicine DoctorTaking people
- Limoges university hospitalLimoges, FranceContact: Philippe COURATIER, ProfessorTaking people
- Hopital de la TimoneMarseille, FranceContact: Shahram ATTARIAN, ProfessorTaking people
- Hôpital Gui ChauliacMontpellier, FranceContact: Elisa De La Cruz, Medicine DoctorTaking people
- CHU de NiceNice, FranceContact: Marie-Hélène SORIANI SORIANI, Medicine DoctorTaking people
- Hôpital de la Pitié-SalpêtrièreParis, FranceContact: Gaëlle BRUNETEAU, ProfessorTaking people
- CHU de ToursTours, FranceContact: Philippe CORCIA, ProfessorTaking people
About the trial
What the trial wants to find out
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. Studies have shown the importance of weight loss at the time of diagnosis and during the progression of the disease. However, the pathophysiological mechanisms behind weight loss remain unknown. Identifying these mechanisms could make it possible to propose an effective therapeutic strategy against weight loss for ALS patients, which could improve their survival and quality of life. In this context, the investigators are proposing an innovative multidisciplinary project aimed at structuring a large Franco-German cohort to identify the markers associated with weight loss in ALS.
Read full original descriptionShow less
Participants will undergo high quality standard care for ALS patients. In addition, participants will be asked to respond different questionnaires and blood samples will be taken for analysis to identify biological markers.
The group in the trial
- ALL participantsOther group
ALS patients will be stratified in 4 groups according to the weight loss percentage: a) no weight loss; b) \<5% of weight loss; c) 5-10% of weight loss; d) \>10% of weight loss. In order to identify the genomic, metabolomic, metabolic, neurofilaments, and inflammation markers associated to weight loss.
Treatment: Blood sample
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis
- Plain-language title
- Study of factors linked to weight loss in amyotrophic lateral sclerosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 August 2026